جستجوی استاد راهنمای دانشگاهی

Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.

• Childhood Diabetes
• Type 1 Diabetes
• Virology and Diabetes
• +۴ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Dr. Yogambha Ramaswamy is a Senior Lecturer in the School of Biomedical Engineering at The University of Sydney and a member of the Sydney Nano Institute. She holds a Master’s in Biotechnology from the University of Queensland and a PhD in Biomedical Engineering from the University of Sydney (2009). Her postdoctoral career began as a Vice-Chancellor’s Postdoctoral Research Fellow at the University of New South Wales, followed by a Peter Doherty Early Career Fellowship in 2013 before joining the University of Sydney in 2015. Dr. Ramaswamy’s research focuses on biomaterials, tissue engineering, and mechanobiology, with a particular emphasis on developing calcium silicate-based ceramics and biopolymers for orthopedic and regenerative applications. Her recent work explores the role of physical cues in modulating stem and cancer cell behavior. She teaches courses such as AMME1961 (Introduction to Biomedical Engineering B) and AMME5962 (Introduction to Mechanobiology). Her research has been supported by grants including the NHMRC Early Career Fellowship and collaborations with institutions like the CSIR-Indian Institute of Chemical Technology and the University of Otago. Her publications span biomaterials, nanotechnology, and mechanobiology, with recent work addressing atherosclerosis, hydrogel design, and nanomedicine. She currently supervises PhD students Frank (biomaterials) and Alexander (atherosclerosis research).

• Biomaterials
• Tissue Engineering
• Mechanobiology
• +۳ مورد دیگر

Associate Professor Colin Jackson is affiliated with the Research School of Chemistry at the Australian National University College of Physical & Mathematical Sciences . His research spans enzyme engineering, synthetic biology, and protein evolution, with a focus on directed evolution approaches for biocatalysis and molecular biophysics. Former CSIRO and Weizmann Institute researcher Key projects: plastic degradation enzymes, viral protease inhibitors, noncanonical amino acid incorporation His work leverages ancestral sequence reconstruction and machine learning to explore protein sequence spaces, with notable outputs in fitness landscape analysis and biocatalytic applications . Recent publications highlight advancements in: Plastic biodegradation enzyme engineering Antiviral peptide design targeting SARS-CoV-2 Fluorinated noncanonical amino acids for protein studies Marine bacterial transport proteins Organophosphate resistance mechanisms While no formal awards are listed in this data, his research portfolio demonstrates strong industry and biomedical applications through: ANU Researcher Portal publications Collaborative projects with international institutions 50+ funded projects including gene therapy platforms and food waste solutions

• Enzyme Biochemistry
• Protein Engineering
• Directed Evolution
• +۳ مورد دیگر

Andrew Currie is a Professor and Associate Dean (Research & Innovation) at Murdoch University's School of Medical, Molecular and Forensic Sciences, within the College of Environmental and Life Sciences. He leads the Sepsis Diagnostics Research Group at the Centre for Molecular Medicine and Innovative Therapeutics and co-heads the Neonatal Infection and Immunity Team with Clinical Professor Tobias Strunk at the Wesfarmers Centre of Vaccine & Infectious Diseases at Telethon Kids Institute. His research focuses on immunology and infectious diseases in pediatric populations, particularly sepsis diagnostics and neonatal immunity. Education: PhD (Immunology, University of Western Australia, 2001); BSc (Biotechnology with Honors, Murdoch University, 1997). Research Interests: Sepsis diagnostics, innate immunity mechanisms in neonates, medical biotechnology for diagnostics (e.g., biosensors), and translational research in pediatric infections. Collaborates internationally with institutions in Canada, Denmark, the UK, US, and China. Aims to reduce sepsis burden in vulnerable populations through advanced molecular methods and interdisciplinary partnerships. Key Affiliations: Lead of Sepsis Diagnostics Research Group (Murdoch University), Senior Lecturer in Immunology, Honorary Associate at Kids Research Institute Australia. Past roles include leadership in the Centre for Molecular Medicine and Innovative Therapeutics. Scientific Contributions: Over 100 peer-reviewed articles focusing on sepsis biomarkers, neonatal immunity, tick-borne diseases, and clinical trials for interventions like vitamin C and probiotics in critical illness. Active in developing precision medicine approaches for neonatal sepsis. Grants & Funding: Co-leads major projects on sepsis diagnostics and neonatal infection, supported by national and international grants. Collaborates on multi-institutional initiatives. Labs/Teams: Sepsis Diagnostics Research Group (Murdoch) and Neonatal Infection and Immunity Team (Telethon Kids Institute). Works closely with the Personalised Medicine Centre and Health Futures Institute.

• Sepsis
• Innate Immunity
• Neonatal Immunology
• +۵ مورد دیگر

Dr. Maryam Roudbary is an Adjunct Senior Lecturer at the Westmead Clinical School, part of the Sydney Medical School, University of Sydney. She joined the Sydney Infectious Diseases Institute (Sydney ID) in 2023 as a researcher affiliated with the University of Sydney and employed by NSW Health and Research Network as a Senior Researcher in Mycology. Previously, she served as an Associate Professor at Iran University of Medical Sciences (2015–2022), leading research projects and supervising Master’s and PhD students in medical mycology and fungal infections. Her PhD in Medical Mycology focused on antifungal resistance mechanisms and new therapeutic strategies. Current research priorities include developing novel antifungal agents against drug-resistant fungi, understanding resistance mechanisms, and addressing challenges outlined in the WHO’s 2022 Fungal Priority Pathogen List. She is an editor for several mycology journals and co-authored The Book of Fungal Pathogens (2022). Roudbary’s work spans epidemiological studies, clinical sampling, and collaborations in One Health AMR initiatives. She leads projects on fungal diversity exploration (e.g., Vietnam citizen science initiatives) and evaluates natural compounds (e.g., thymus extracts, nanoparticles) for antifungal efficacy. Recent grants include a 2025 project on antifungal peptide-based therapeutics. Her research emphasizes biofilm formation in filamentous fungi, Candida species pathogenesis, and fungal co-infections in immunocompromised patients, including those with severe COVID-19. Key findings include the prevalence of azole-resistant Candida species in Iran and the role of gene expression (e.g., CDR1 , HWP1 ) in drug resistance. Roudbary’s contributions include over 100 peer-reviewed articles, grants focusing on antifungal innovation, and active roles in international mycology networks. She bridges clinical and research domains through translational studies targeting critical fungal health challenges.

• Medical Mycology
• Antimicrobial Resistance
• Infectious Diseases
• +۴ مورد دیگر

Richard S. Bradbury is a Professor at James Cook University, renowned for his research in parasitology, infectious diseases, and public health. His work focuses on soil-transmitted helminths, Strongyloides species, and zoonotic infections, with a particular emphasis on their epidemiology, diagnostics, and global health implications. He has contributed to studies on ascariasis, schistosomiasis, and emerging parasitic infections, often collaborating with international teams to address public health challenges in regions such as the Solomon Islands, Mississippi, and India. Bradbury’s research spans clinical, diagnostic, and molecular aspects of parasitology, including the development of improved diagnostic tools and understanding parasite life cycles. He has published extensively on Strongyloides stercoralis, exploring its autoinfective stages, zoonotic potential, and global prevalence. His work also addresses public health strategies to combat neglected tropical diseases, particularly in under-resourced communities. Recent studies include investigations into hookworm fixatives, Ebola virus persistence in survivors, and the prevalence of Strongyloides in high-risk populations. Bradbury’s contributions highlight the intersection of veterinary and human health, emphasizing One Health approaches to combat parasitic infections.

• Parasitology
• Infectious Diseases
• Public Health
• +۳ مورد دیگر

Professor Mark Polizzotto is Professor of Medicine in the College of Science and Medicine at the Australian National University (ANU), Group Leader in Cancer and Genome Science at the John Curtin School of Medical Research, and leads the Clinical Hub for Interventional Research (CHOIR). Previously, he served as a Senior Staff Haematologist at The Canberra Region Cancer Centre, Canberra Hospital. His research interests focus on the intersection of immunity, infection and cancer, with particular emphasis on developing new therapies to prevent and treat malignancy, especially infection-related cancers. His work spans Cancer Immunotherapy , Cancer Target Therapies , Infectious Disease Immunotherapy , HIV/HIV-related malignancies , and Global Oncology , with specific expertise in Human Herpesvirus-8 , Epstein Barr Virus , and Human Papillomavirus . His clinical specialties include Haematology , Infectious Diseases , and Tumour Immunology . His recent publications demonstrate a strong focus on clonal hematopoiesis in HIV patients, lymphoma outcomes in immunocompromised individuals, and therapeutic approaches for viral infections including SARS-CoV-2. His work frequently addresses the intersection of chronic viral infections and cancer development, with particular attention to global health applications. The Tony Ayers Award (2022) Professor Polizzotto has led multiple international clinical trials, including work on viral and HIV-associated cancers that has influenced global guidelines. He co-led the development of an oral immunomodulator for Kaposi sarcoma which led to the first new drug approval for KS in over 20 years. During the SARS-CoV-2 pandemic, he led international randomized trials of immunotherapies for COVID-19 at the invitation of the U.S. National Institutes of Health. He has a strong commitment to diversity and inclusion in clinical trials and to clinical research capacity development in resource-limited settings, having led trial capacity building efforts in West Africa and Indonesia for the U.S. National Institutes of Health.

• Cancer Immunotherapy
• Infectious Disease Immunotherapy
• HIV-Related Malignancies
• +۶ مورد دیگر

Dr. Kim O'Sullivan is a Senior Research Fellow and head of the Translational Kidney Therapies Group at the Centre for Inflammatory Diseases (CID), Monash Health Translational Precinct, affiliated with Monash University’s Faculty of Medicine, Nursing and Health Sciences. She holds a PhD in Immunology from Monash University and completed her undergraduate and Master’s studies in Anatomy and Structural Biology at the University of Otago, New Zealand. Her work is centered on developing novel therapies for autoimmune kidney diseases, particularly ANCA-associated vasculitis (AAV), glomerulonephritis, and lupus nephritis. Her research focuses on: Neutrophil Extracellular Traps (NETs) and their role in inflammation Gene therapy using adeno-associated viral vectors to deliver DNase I Therapeutic potential of bacterial exosomes Gut microbiome interactions, especially Muribaculaceae and SCFAs Immune tolerance and host defense preservation Her recent publications (2023–2024) reflect a strong trend in translational immunology, with emphasis on microbiome-immune crosstalk, novel biologics, and gene-based interventions. She has published in high-impact journals such as Frontiers in Immunology , International Journal of Molecular Sciences , and Journal of Immunology . Her scientific contributions have been recognized through several awards: Australian and New Zealand Society of Nephrology Young Investigator Award (Winner, 2016) ANZSN Basic Science Award (Finalist, 2020) Multiple ANZSN Travel Awards (2014, 2016, 2017) Kim O'Sullivan actively supervises Honours and PhD students and leads multiple research projects funded by NHMRC and MRFF. She serves on the ANZSN Scientific Programme and Awards Committee (SPARC), is a Review Editor for Frontiers in Immunology , and sits on the editorial boards of International Journal of Molecular Sciences and Journal of Integrated Medicine in Nephrology and Andrology . She is also a peer reviewer for top journals including Journal of Clinical Investigation and Kidney International . She leads the CID weekly seminar series and chaired the ImmuMON21 symposium. Her commitment to equity in STEM includes mentoring through BrainSTEM and past involvement in the ANZSN Equity, Diversity and Inclusion Committee.

• Immunology
• Autoimmune Diseases
• Kidney Disease
• +۱۳ مورد دیگر

Michelle Tate is an Adjunct Associate Professor (Research) at the Hudson Institute of Medical Research, where she leads the Viral Immunity and Immunopathology research group and serves as Deputy Centre Head at the Centre for Innate Immunity and Infectious Disease. She earned her PhD in Microbiology and Immunology from the University of Melbourne in 2010 and has since established herself as a leading researcher in viral immunology and pathogenesis. Institution: Hudson Institute of Medical Research School: Centre for Innate Immunity and Infectious Disease Academic Rank: Adjunct Associate Professor Email: michelle.tate@hudson.org.au Education: PhD in Microbiology and Immunology, University of Melbourne (2010) Dr. Tate's research centers on the molecular mechanisms driving hyperinflammation and severe disease during viral infections, particularly influenza A virus. Her work investigates how the host immune response—specifically inflammasome signaling, pyroptosis, and interferon pathways—contributes to immunopathology. She aims to develop host-directed therapies that modulate inflammation to reduce lung damage and improve outcomes in respiratory viral diseases. Her research integrates animal models, molecular immunology, and translational approaches to bridge basic science with clinical applications. Analysis of her recent publications reveals a strong focus on inflammasome biology (especially NLRP3 and gasdermin-mediated pyroptosis), host-pathogen interactions in influenza, and immune protection in non-traditional sites such as the male reproductive tract. Her work spans immunology, virology, pulmonary disease, and therapeutic development, with an emphasis on targeting innate immune pathways for treatment. Australian Institute of Policy and Science (AIPS) Young Tall Poppy Science Award (2018) Christina Fleischmann Memorial Award (2016) Victorian Infection and Immunity Network Career Development Award (2016) Commendation, Victorian Premier’s Award for Health & Medical Research (2011) Chancellor's and Dean's Prize for PhD Excellence (2011) Bridging Postdoctoral Fellowship (2011) Dr. Tate actively contributes to the scientific community through NHMRC and MRFF grant review panels, editorial roles in journals such as Journal of Virology and Pathogens, and leadership in the Australasian Virology Society. She mentors students and collaborates with clinical and commercial partners to translate her findings into novel therapies. Her lab is engaged in multiple funded projects focused on silicosis, influenza immunopathology, and host-directed antiviral strategies, reflecting her commitment to impactful, interdisciplinary research.

• Viral Pathogenesis
• Immunology
• Influenza A Virus
• +۹ مورد دیگر

Dr. José A. Quinteros is a Lecturer in Poultry Health at the Sydney School of Veterinary Science, University of Sydney. He holds a DVM from the University of Chile (2004), followed by an MVSc and PhD. His career began in 2005 as a field veterinarian at Sopraval S.A., where he specialized in diagnosing and treating prevalent poultry diseases like Fowl Cholera, avian influenza H1N1, and Ornithobacterium rhinotracheale (ORT). He later joined the Quality Assurance team, overseeing national/international regulatory programs. Research focuses on avian virology, including coronaviruses (e.g., infectious bronchitis virus) and bacterial pathogens. His work explores genomics, pathogenesis, and diagnostic tools for poultry diseases. Notable projects include optimizing protein nutrition for poultry resilience in tropical climates (2024 SSEAC Grant) and reconnecting with the Australian poultry industry for critical research (2023 SSVS Grant). He has been featured in media, including an ABC interview (January 2025) discussing avian flu H5N1 in humans. He is a member of the Sydney Southeast Asia Centre and contributes to interdisciplinary collaborations.

• Avian Virology
• Poultry Health Management
• Infectious Disease Pathogenesis
• +۳ مورد دیگر

Dr Brent McParland is a Senior Lecturer at the Sydney Pharmacy School, University of Sydney, and a member of the Charles Perkins Centre. His work bridges respiratory pharmacology, parasitology, and reproductive medicine with clinical applications. His primary research investigates mechanisms of exaggerated airway narrowing in asthma and COPD, focusing on airway smooth muscle dynamics, autacoid pharmacology (5HT, NO, Bradykinin, PGs, LTs, Histamine), and the role of extracellular matrix. He also leads pioneering research into whether Australian ticks cause Lyme-like illness, examining Babesia and Theileria pathogens through molecular detection methods. His work extends to reproductive medicine and drugs in sport, aligning with the Charles Perkins Centre's themes of obesity, diabetes, cardiovascular disease, infection, and maternal health. Analysis of his 15 most recent publications reveals a dominant respiratory focus (73% of articles), particularly on airway smooth muscle physiology in asthma/COPD, with significant contributions to parasitology (13%) regarding Australian tick-borne diseases. His methodological approaches emphasize cellular signaling, pathogenesis, and pathology, often utilizing in vitro models and molecular characterization techniques. Dr McParland has secured competitive research funding including: 2014: Australias Lyme-Like Illness grant (Australian Respiratory Council) 2013: NHMRC Project Grant on COPD airway mechanics 2006: Ramaciotti Foundation grant on asthma fluid lining 2006: University of Sydney Newly Appointed Staff grant 2006: Asthma Foundation of NSW award on cold-induced exacerbations He teaches core pharmacology courses including Pharmacology Fundamentals, Respiratory Diseases (Asthma, COPD, PAH), and Autacoid Pharmacology, while contributing to the Charles Perkins Centre's multidisciplinary research on metabolic, infectious, and reproductive health conditions through his expertise in airway pathophysiology and vector-borne disease mechanisms.

• Respiratory Pharmacology
• Parasitology
• Reproductive Medicine
• +۳ مورد دیگر

Professor Xiaowei Wang is a leading academic at the Baker Heart and Diabetes Institute , where she heads the Molecular Imaging and Nanotherapeutics laboratory and co-leads the Heart Attack Program and Centre for Cardiometabolic mRNA Therapy . She holds adjunct and honorary academic appointments at the University of Melbourne, La Trobe University, Monash University, Swinburne University, and Torrens University. Professor Wang earned her PhD from Monash University and is a Fellow of the Australian Academy of Health Sciences (FAHA), Cardiac Society of Australia and New Zealand (FCSANZ), and European Society of Cardiology (FESC). Her research integrates physics, chemistry, biology, and biotechnology to develop clinical-ready diagnostic and therapeutic solutions for cardiovascular disease. Her work focuses on preclinical molecular imaging using advanced technologies like MRI, PET, and photoacoustic imaging to enable early diagnosis and real-time monitoring of treatments. She pioneers mRNA therapeutics and vaccines delivered via micro- and nano-particles to prevent heart attacks, strokes, and inflammation with minimal side effects. Key trends in her publications highlight targeted drug delivery , thrombosis prevention , Nanotherapeutics , and translational cardiovascular research . Her studies often explore the intersection of molecular imaging , biomedical engineering , and clinical applications . Scientific awards and recognitions: National Heart Foundation Future Leader Fellowship Level 2 Baker Institute Sir Laurence Muir Prize World Molecular Imaging Society Mid Career Award Inaugural Fellow of the Australian Society of Molecular Imaging National Heart Foundation Paul Korner Innovation Award Inaugural Women of Colour in STEM Award AVBS Achievement and Career Development Award 40 Under 40 Most Influential Asian-Australian Award Finalist Professor Wang is also deeply committed to equity and mentorship, chairing the Baker Institute’s Mentoring Committee and serving on leadership teams for the Women in Molecular Imaging Network and the Gender Equity and Diversity Committee. She has received over 27 national and international travel grants, 18 research prizes, and 14 Young Investigator Awards, underscoring her impact in the field.

• Molecular Imaging
• Nanotherapeutics
• Cardiovascular Disease
• +۳ مورد دیگر

Professor Lisa Wood is the Pro Vice Chancellor of the College of Health, Medicine and Wellbeing at the University of Newcastle. She holds a PhD in Nutrition and Dietetics and has over 20 years of research experience in nutritional biochemistry, focusing on the interplay between diet, inflammation, and respiratory diseases like asthma and cystic fibrosis. Her work bridges nutrition science and respiratory medicine, emphasizing dietary guidelines for disease management. She leads the Nutrition and Metabolism Theme at HMRI and has supervised 22 PhD and 2 Masters students. Education: BSc (Honours) from the University of Sydney, PhD in Nutrition & Dietetics from the University of Newcastle. Professional roles include former Head of the School of Biomedical Sciences and Pharmacy (2020–2025) and interim Pro Vice Chancellor Student Engagement (2023–2024). Leadership in national organizations includes President of the Nutrition Society of Australia (2016–2021) and Chair of Asthma Australia’s Research Advisory Committee. Research Interests: Mechanisms of dietary factors (e.g., antioxidants, fatty acids, soluble fiber) on airway inflammation; obesity-related asthma; translational nutrition interventions. Key contributions include demonstrating that high fruit/vegetable diets reduce asthma exacerbations and identifying saturated fatty acids’ impact on bronchodilator efficacy. Her work informs clinical guidelines, including the Australian Asthma Handbook. Awards: 2022 Nutrition Society of Australia Medal, 2006 NSW Tall Poppy Award, and multiple mid-career recognitions. Over 210 publications (H-index 57/Scopus). Labs/Teams: Leads the Nutrition Research group in the Priority Research Centre for Asthma and Respiratory Diseases at HMRI. Collaborates with bariatric surgeons and clinical trial networks.

• Nutrition
• Respiratory Diseases
• Inflammation
• +۷ مورد دیگر

Dr Sheryl Chang is a Research Associate in the Modelling and Simulation Research Group at the School of Computer Science, University of Sydney. She holds a PhD in computational epidemiology (2021) and specializes in modeling infectious disease transmission and intervention strategies, integrating social and behavioral factors. Her work has been validated in multiple epidemic scenarios and recognized by global health organizations like the WHO and Lancet COVID-19 Commission. Teaching: She instructs courses such as System Dynamics Modelling for Project Management (PMGT5886) and Social Network Analysis Principles (OLET2346) . Her research focuses on pandemic dynamics, pathogen evolution, and the impact of human behavior on disease spread. Awards: Recipient of the prestigious Lord Robert May Prize (2019-2020) for best paper in Journal of Biological Dynamics , and 2023 Dean’s commendation for teaching excellence in the Faculty of Engineering. Research Grants: Lead investigator on the 2022 Sydney Institute for Infectious Diseases grant Modelling the impact of opinion dynamics on the COVID-19 pandemic in Australia . Labs/Teams: Active member of the Modelling and Simulation Research Group, collaborating on agent-based models for public health policy design and genomic epidemiology of pathogens like Salmonella and SARS-CoV-2.

• Computational Epidemiology
• Infectious Disease Modeling
• Public Health
• +۳ مورد دیگر